MET and cancer: A synergy between MET inhibition (using MK8033 [53], capmatinib [54], crizotinib [55], PHA-665752 [30, 45, 56] or SU11274 [29]) and chemotherapy (carboplatin [53], paclitaxel [53, 54], cisplatin [30, 45, 55], doxorubicin [29, 56] or bortezomib [29]) has been reported in ovarian [53–55], gastric [56], osteosarcoma [45] and MDR multiple myeloma [29] cancer cell lines.